Studies of insulin action in patients at increased vascular risk: modulation by anti-hypertensive and endocrine replacement therapy
Completed
- Conditions
- Hypertension, type two diabetes, hypopituitarismNutritional, Metabolic, EndocrineHypertension
- Registration Number
- ISRCTN84921696
- Lead Sponsor
- Royal Group Hospitals Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
1. Under 65 years old
2. Protocol one: essential hypertension, mild or newly diagnosed
3. Protocol two: type two diabetes and hypertension
4. Protocol 3: hypopituitarism, female, low basal DHEA levels
Exclusion Criteria
1. Secondary hypertension
2. Obesity
3. Cardiac, renal or hepatic disease
4. History of gout
5. Those in receipt of any additional medications that may affect insulin action
6. Type two diabetics with dipstick positive proteinuria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin resistance.
- Secondary Outcome Measures
Name Time Method Quality of life following dehydroepiandrosterone replacement.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie insulin resistance in hypertension and type 2 diabetes patients with hypopituitarism?
How do anti-hypertensive therapies modulate insulin sensitivity in high vascular risk populations?
What endocrine replacement strategies improve metabolic outcomes in hypopituitarism-related vascular disease?
What biomarkers predict response to combination anti-hypertensive and endocrine replacement therapies in vascular risk patients?
How does this trial's approach compare to other glucose-lowering agents in managing vascular complications of diabetes?